Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies

ARV-110, a novel proteolysis-targeting chimera (PROTAC), has been reported to show satisfactory safety and tolerability for prostate cancer therapy in phase I clinical trials. However, there is a lack of bioanalytical assays for ARV-110 determination in biological samples. In this study, we develope...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi-Thao-Linh, Kim, Jin Woo, Choi, Hae-In, Maeng, Han-Joo, Koo, Tae-Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954769/
https://www.ncbi.nlm.nih.gov/pubmed/35335338
http://dx.doi.org/10.3390/molecules27061977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954769/
https://www.ncbi.nlm.nih.gov/pubmed/35335338
http://dx.doi.org/10.3390/molecules27061977

Ejemplares similares